NFKB1 and cancer: PPAR-γ is a target for integrative therapies that simultaneously act on tumors and their microenvironment [70] because it regulates gene expression in multiple signaling pathways, including B-cell lymphoma 2 (BCL-2), nuclear factor kappa light-chain enhancer of activated B cells (NF-κB), tumor suppressor p53 (p53) and cyclooxygenase-2 (COX-2), which play a role in various diseases, including cancer [70].